USD 0.73
(-1.35%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 1.14 Million USD | -56.67% |
2022 | 1 Million USD | 7.14% |
2021 | 933.65 Thousand USD | 15.97% |
2020 | 805.08 Thousand USD | -8.49% |
2019 | 879.75 Thousand USD | -11.66% |
2018 | 995.89 Thousand USD | 96.51% |
2017 | 506.79 Thousand USD | 84.37% |
2016 | 274.87 Thousand USD | -21.55% |
2015 | 350.37 Thousand USD | -38.12% |
2014 | 566.23 Thousand USD | 103.38% |
2013 | 278.41 Thousand USD | 362.24% |
2012 | 60.23 Thousand USD | 48.51% |
2011 | 40.55 Thousand USD | 27303.38% |
2010 | 148.00 USD | -98.31% |
2009 | 8737.00 USD | 0.0% |
2008 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -38.41 Thousand USD | -155.14% |
2024 Q1 | 69.66 Thousand USD | 197.76% |
2023 Q1 | 119.75 Thousand USD | -42.98% |
2023 Q4 | -71.26 Thousand USD | -111.72% |
2023 Q3 | 608.11 Thousand USD | 84.08% |
2023 Q2 | 330.34 Thousand USD | 175.85% |
2023 FY | 433.4 Thousand USD | -56.67% |
2022 Q3 | 347.67 Thousand USD | 46.38% |
2022 Q2 | 237.51 Thousand USD | 15.79% |
2022 FY | 1 Million USD | 7.14% |
2022 Q1 | 205.12 Thousand USD | -39.72% |
2022 Q4 | 210.03 Thousand USD | -39.59% |
2021 Q3 | 203.49 Thousand USD | -1.85% |
2021 FY | 933.65 Thousand USD | 15.97% |
2021 Q4 | 340.26 Thousand USD | 67.21% |
2021 Q2 | 207.33 Thousand USD | 13.57% |
2021 Q1 | 182.55 Thousand USD | -8.59% |
2020 Q2 | 97.52 Thousand USD | -51.79% |
2020 Q3 | 305.55 Thousand USD | 213.31% |
2020 FY | 805.08 Thousand USD | -8.49% |
2020 Q1 | 202.28 Thousand USD | -6.29% |
2020 Q4 | 199.72 Thousand USD | -34.64% |
2019 FY | 879.75 Thousand USD | -11.66% |
2019 Q1 | 181.52 Thousand USD | -11.5% |
2019 Q2 | 167.76 Thousand USD | -7.58% |
2019 Q3 | 314.6 Thousand USD | 87.53% |
2019 Q4 | 215.86 Thousand USD | -31.38% |
2018 FY | 995.89 Thousand USD | 96.51% |
2018 Q2 | 249.61 Thousand USD | -15.17% |
2018 Q1 | 294.25 Thousand USD | 83.93% |
2018 Q4 | 205.1 Thousand USD | -16.94% |
2018 Q3 | 246.92 Thousand USD | -1.08% |
2017 Q4 | 159.97 Thousand USD | 29.19% |
2017 FY | 506.79 Thousand USD | 84.37% |
2017 Q1 | 138.17 Thousand USD | 29.05% |
2017 Q3 | 123.82 Thousand USD | 46.0% |
2017 Q2 | 84.81 Thousand USD | -38.62% |
2016 Q4 | 107.07 Thousand USD | -0.97% |
2016 FY | 274.87 Thousand USD | -21.55% |
2016 Q3 | 108.12 Thousand USD | 122.22% |
2016 Q2 | 48.65 Thousand USD | 341.44% |
2016 Q1 | 11.02 Thousand USD | -85.98% |
2015 Q3 | 66.01 Thousand USD | -56.12% |
2015 Q2 | 150.44 Thousand USD | 172.02% |
2015 Q1 | 55.3 Thousand USD | 23.89% |
2015 FY | 350.37 Thousand USD | -38.12% |
2015 Q4 | 78.6 Thousand USD | 19.06% |
2014 FY | 566.23 Thousand USD | 103.38% |
2014 Q4 | 44.64 Thousand USD | -82.99% |
2014 Q1 | 39.13 Thousand USD | 44.31% |
2014 Q2 | 219.92 Thousand USD | 461.94% |
2014 Q3 | 262.52 Thousand USD | 19.37% |
2013 Q3 | 81.65 Thousand USD | -2.24% |
2013 Q1 | 86.12 Thousand USD | 85.21% |
2013 Q4 | 27.12 Thousand USD | -66.79% |
2013 Q2 | 83.52 Thousand USD | -3.02% |
2013 FY | 278.41 Thousand USD | 362.24% |
2012 Q3 | -18.34 Thousand USD | -178.91% |
2012 Q4 | 46.5 Thousand USD | 353.45% |
2012 FY | 60.23 Thousand USD | 48.51% |
2012 Q2 | 23.25 Thousand USD | 163.34% |
2012 Q1 | 8829.00 USD | -71.43% |
2011 Q1 | - USD | 100.0% |
2011 Q3 | 9103.00 USD | 1543.14% |
2011 Q4 | 30.9 Thousand USD | 239.45% |
2011 FY | 40.55 Thousand USD | 27303.38% |
2011 Q2 | 554.00 USD | 0.0% |
2010 FY | 148.00 USD | -98.31% |
2010 Q3 | - USD | 0.0% |
2010 Q4 | -4753.00 USD | 0.0% |
2010 Q2 | - USD | -100.0% |
2010 Q1 | 148.00 USD | 100.79% |
2009 Q4 | -18.7 Thousand USD | 0.0% |
2009 FY | 8737.00 USD | 0.0% |
2009 Q3 | - USD | -100.0% |
2009 Q2 | 8287.00 USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Akoya Biosciences, Inc. | 56.3 Million USD | 97.966% |
AngioDynamics, Inc. | 154.69 Million USD | 99.26% |
AtriCure, Inc. | 300.37 Million USD | 99.619% |
Avinger, Inc. | 2 Million USD | 42.821% |
Azenta, Inc. | 263.14 Million USD | 99.565% |
BioLife Solutions, Inc. | 46.75 Million USD | 97.55% |
The Cooper Companies, Inc. | 2.35 Billion USD | 99.951% |
Daxor Corporation | 1.1 Million USD | -3.793% |
Ekso Bionics Holdings, Inc. | 9.07 Million USD | 87.385% |
Femasys Inc. | 691.9 Thousand USD | -65.529% |
GlucoTrack, Inc. | -13 Thousand USD | 8909.977% |
Harvard Bioscience, Inc. | 60.86 Million USD | 98.118% |
Hologic, Inc. | 2.22 Billion USD | 99.949% |
ICU Medical, Inc. | 739.87 Million USD | 99.845% |
Intuitive Surgical, Inc. | 4.72 Billion USD | 99.976% |
KORU Medical Systems, Inc. | 16.7 Million USD | 93.145% |
LeMaitre Vascular, Inc. | 127.04 Million USD | 99.099% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 1059.781% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 1059.781% |
Masimo Corporation | 1 Billion USD | 99.886% |
Microbot Medical Inc. | -106 Thousand USD | 1180.469% |
Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | 96.539% |
Merit Medical Systems, Inc. | 583.87 Million USD | 99.804% |
Nephros, Inc. | 8.4 Million USD | 86.374% |
NovoCure Limited | 381.05 Million USD | 99.699% |
NEXGEL, Inc. | 619 Thousand USD | -85.024% |
NEXGEL, Inc. | 619 Thousand USD | -85.024% |
Singular Genomics Systems, Inc. | -558 Thousand USD | 305.25% |
OraSure Technologies, Inc. | 179.42 Million USD | 99.362% |
Pro-Dex, Inc. | 14.55 Million USD | 92.129% |
Pulse Biosciences, Inc. | -1.2 Million USD | 194.888% |
Precision Optics Corporation, Inc. | 5.79 Million USD | 80.246% |
QuidelOrtho Corporation | 1.49 Billion USD | 99.923% |
Repligen Corporation | 315.22 Million USD | 99.637% |
Sanara MedTech Inc. | 57.13 Million USD | 97.996% |
STAAR Surgical Company | 252.65 Million USD | 99.547% |
Sharps Technology, Inc. | -891.24 Thousand USD | 228.505% |
Utah Medical Products, Inc. | 30.03 Million USD | 96.187% |
DENTSPLY SIRONA Inc. | 2.08 Billion USD | 99.945% |
Jin Medical International Ltd. | 6.78 Million USD | 83.12% |